{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"326"},{"groupId":"OG001","value":"253"}]}],"title":"Any adverse event"},{"categories":[{"measurements":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"45"}]}],"title":"Serious adverse event"}],"denoms":[{"counts":[{"groupId":"OG000","value":"336"},{"groupId":"OG001","value":"282"}],"units":"Participants"}],"description":"The intensity of AEs was graded according to the NCI Common Terminology Criteria for Adverse Events v 4.0 (CTCAE) on a five-point scale (Grade 1 to 5: Mild, Moderate, Severe, Life-threatening and Death). A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution, for example is life-threatening, requires hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or requires intervention to prevent one or other of the outcomes listed above.","groups":[{"description":"Participants received continuous oral doses of vemurafenib (RO5185426) 960 mg twice a day. Participants took four 240 mg tablets in the morning and four 240 mg tablets in the evening (960 mg twice a day for a total daily dose of 1920 mg).","id":"OG000","title":"Vemurafenib"},{"description":"Dacarbazine was administered intravenously 1000 mg/m˄2 up to 60 minutes on Day 1 of every 3 weeks (3 weeks was one cycle length).","id":"OG001","title":"Dacarbazine"}],"paramType":"NUMBER","populationDescription":"The safety population was defined as all treated participants who had at least one on-study assessment. The safety population was analyzed according to the treatment received.","reportingStatus":"POSTED","timeFrame":"From randomization (initiated January 2010) until December 30, 2010.","title":"Number of Participants With Adverse Events (AEs)","type":"SECONDARY","unitOfMeasure":"participants"}